Paper - WANFANG MED ONLINE

You Position: Home > Paper

中华预防医学会放射卫生专业委员会第六届委员会换届大会暨"思变求新笃行致远"放射卫生全国学术交流培训会顺利召开

( views:1, downloads:0 )

Author:: No author available

Journal Title:: International Journal of Radiation Medicine and Nuclear Medicine

Issue:: 12

DOI:: 10.3760/cma.j.issn.1673-4114.2023.12.102

Key Word:: No keyword available

Abstract： 2023年11月24日至26日，中华预防医学会放射卫生专业委员会（以下简称专委会）在广东省汕头市召开了第六届委员会换届大会暨"思变求新笃行致远"放射卫生全国学术交流培训会。专委会委员、各科研院所、各省市疾控中心、卫生监督所、职业病防治院等代表190余人参加此次大会。

Reference

[1]李亚明.一体化全身PET/MR设备：现代医学影像学的新利器[J].2021,(11).
[2]Guohua Shen,Huan Ma,Fuwen Pang,etc.Correlations of 18F-FDG and 18F-FLT uptake on PET with Ki-67 expression in patients with lung cancer: a meta-analysis[J].2018,59(2).
[3]Delgado Bolton Roberto C.,Aide Nicolas,Colletti Patrick M.,etc.EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging[J].2021,48(10).
[4]Han, Eun Ji,Park, Hye Lim,Lee, Yong Seok,etc.Clinical usefulness of post-treatment FDG PET/CT in patients with ovarian malignancy[J].2016,30(9).
[5]Yorito, Yamamoto,Hiroyoshi, Oguri,Ruriko, Yamada,etc.Preoperative evaluation of pelvic masses with combined 18F-fluorodeoxyglucose positron emission tomography and computed tomography.[J].2008,102(2).
[6]Hong, Zhihui,Mao, Xinping,You, Jiaxi,etc.An Evaluation of HER2-Positive Ovarian Carcinoma Xenografts: From a Novel Therapy to a Noninvasive Monitoring Method[J].2018,33(9).
[7]C. Riola-Parada,L. García-Cañamaque,V. Pérez-Dueñas,etc.Simultaneous PET/MRI vs. PET/CT in oncology. A systematic review[J].2016,(5).
[8]Soon-Beom Kang,Yong-Sang Song,June-Key Chung,etc.Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer.[J].2012,19(6).
[9]Dale L. Bailey,Kathy P. Willowson.Quantitative SPECT\/CT: SPECT joins PET as a quantitative imaging modality[J].2013,41(S1).
[10]Lindner, Thomas,Altmann, Annette,Kraemer, Susanne,etc.Design and Development of Tc-99m-Labeled FAPI Tracers for SPECT Imaging and Re-188 Therapy[J].2020,61(10).
[11]Yu,H.,Sheng,X.-G.,Du,X.-L.,etc.PET/CT scanning guided intensity-modulated radiotherapy in treatment of recurrent ovarian cancer[J].2012,81(11).
[12]Tsuyoshi Hideaki,Tsujikawa Tetsuya,Yamada Shizuka,etc.Diagnostic value of [18F]FDG PET/MRI for staging in patients with ovarian cancer[J].2020,10(1).
[13]Sangwon,Han,Sungmin,Woo,Chong Hyun,Suh,etc.Performance of pre-treatment 1?F-fluorodeoxyglucose positron emission tomography/computed tomography for detecting metastasis in ovarian cancer: a systematic review and meta-analysis.[J].2018,29(6).
[14]Chulhan, Kim,Hyun Hoon, Chung,So Won, Oh,etc.Differential Diagnosis of Borderline Ovarian Tumors from Stage I Malignant Ovarian Tumors using FDG PET/CT.[J].2013,47(2).
[15]Korhegyi, Zoltan,Rozsa, David,Hajdu, Istvan,etc.Synthesis of Ga-68-Labeled Biopolymer-based Nanoparticle Imaging Agents for Positron-emission Tomography[J].2019,39(5).
[16]Tuulia Vallius,Anniina Peter,Annika Auranen,etc.18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer[J].2016,(1).
[17]Konishi,H.,Takehara,K.,Kojima,A.,etc.Maximum standardized uptake value of fluorodeoxyglucose positron emission tomography/computed tomography is a prognostic factor in ovarian clear cell adenocarcinoma[J].2014,24(7).
[18]Maria Rosana Ponisio*,Farrokh Dehdashti*.A Role of PET Agents Beyond FDG in Gynecology[J].2019,49(6).
[19]Boellaard, Ronald,Delgado-Bolton, Roberto,Oyen, Wim J. G.,etc.FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0[J].2015,42(2).
[20]Tuulia Vallius,Johanna Hynninen,Jukka Kemppainen,etc.18 F-FDG-PET/CT based total metabolic tumor volume change during neoadjuvant chemotherapy predicts outcome in advanced epithelial ovarian cancer[J].2018,45(7).
[21].Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer[J].2019,4(5).
[22]Takagi Hiroaki,Sakamoto Jinichi,Osaka Yasuhiro,etc.Utility of 18F‐fluorodeoxyglucose‐positron emission tomography in the differential diagnosis of benign and malignant gynaecological tumours[J].2018,62(4).
[23]Yuan,H.,Liao,S.,Zhang,Y.,etc.Prognostic predictive value of total lesion glycolysis from 18F-FDG PET/CT in post-surgical patients with epithelial ovarian cancer[J].2013,38(9).
[24]Zohre Momenimovahed,Azita Tiznobaik,Safoura Taheri,etc.Ovarian cancer in the world: epidemiology and risk factors[J].2019,11.
[25]Van den Wyngaert, Tim,Elvas, Filipe,De Schepper, Stijn,etc.SPECT/CT: Standing on the Shoulders of Giants, It Is Time to Reach for the Sky![J].2020,61(9).
[26]Francesca Castellani,Edward C. Nganga,Lucy Dumas,etc.Imaging in the pre-operative staging of ovarian cancer[J].2019,44(2).
[27]Riad, Aladdin,Gitto, Sarah B.,Lee, Hwan,etc.PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response[J].2020,25(24).
[28].Diagnostic value of integrated 1?F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.[J].2018,(Spec).
[29]Jónsdóttir Björg,Ripoll Montserrat Alemany,Bergman Antonina,etc.Validation of 18F-FDG PET/MRI and diffusion-weighted MRI for estimating the extent of peritoneal carcinomatosis in ovarian and endometrial cancer -a pilot study[J].2021,21(1).
[30]Cha Soonmee,Johnson Geoffrey B.,Villanueva‐Meyer Javier E.,etc.PET/MRI: Where might it replace PET/CT?[J].2017,46(5).
[31]Tae-Young,Jung,Shin,Jung,Han-Seung,Ryu,etc.The Application of Magnetic Resonance Imaging-Deformed 11C-Methionine-Positron Emission Tomography Images in Stereotactic Radiosurgery.[J].2019,97(4).
[32].Positron Emission Tomography/Computed Tomography in Platinum-sensitive Recurrent Ovarian Cancer: A Single-center Italian Study[J].2020,40(4).
[33]Kim, Choon-Young,Jeong, Shin Young,Chong, Gun Oh,etc.Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer[J].2015,136(3).
[34]Gallicchio, Rosj,Nardelli, Anna,Venetucci, Angela,etc.F-18 FDG PET/CT metabolic tumor volume predicts overall survival in patients with disseminated epithelial ovarian cancer[J].2017,93.
[35]Prat,J..Staging classification for cancer of the ovary, fallopian tube, and peritoneum[J].2014,124(1).
[36]"ORCID":"http:\/\/orcid.org\/0000-0003-3140-4772Anna Perrone,Giulia Dondi,Giacomo Lima,etc.Potential Prognostic Role of 18F-FDG PET\/CT in Invasive Epithelial Ovarian Cancer Relapse. A Preliminary Study[J].2019,11(5).
[37]Menglong Zheng,Daohai Xie,Chenhuan Pan,etc.Diagnostic value of 18F-FDG PET/MRI in recurrent pelvis malignancies of female patients: a systematic review and meta-analysis[J].1900,39(6).